Abnormal Protein Glycosylation and Activated PI3K/Akt/mTOR Pathway: Role in Bladder Cancer Prognosis and Targeted Therapeutics

• Céu Costa ,

  Contributed equally to this work with: Céu Costa, Sofia Pereira

  Affiliations Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal, ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, Health Sciences Faculty of University Fernando Pessoa, Porto, Portugal

  ⨯
• Sofia Pereira ,

  Contributed equally to this work with: Céu Costa, Sofia Pereira

  Affiliations Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal, ICBAS, Abel Salazar Biomedical Sciences Institute, University of Porto, Porto, Portugal, Health Sciences Faculty of University Fernando Pessoa, Porto, Portugal

  ⨯
• Luís Lima,

  Affiliations Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal, Nucleo de Investigação e Informação em Farmácia - Centro de Investigação em Saúde e Ambiente (CISA), School of Allied Health Sciences – Polytechnic Institute of Oporto, Porto, Portugal, Institute of Pathology and Molecular Immunology of the University of Porto (IPATIMUP), Porto, Portugal

  ⨯
• Andreia Peixoto,

  Affiliation Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal

  ⨯
• Elisabete Fernandes,

  Affiliation Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal

  ⨯
• Diogo Neves,

  Affiliation Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal

  ⨯
• Manuel Neves,

  Affiliation Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal

  ⨯
• Cristiana Gaiteiro,

  Affiliation Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal

  ⨯
• Ana Tavares,

  Affiliations Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal, Department of Pathology, Portuguese Institute of Oncology, Porto, Portugal

  ⨯
• Rui M. Gil da Costa,

  Affiliations Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal, Faculty of Engineering, Laboratory for Process, Environment, Biotechnology and Energy Engineering (LEPABE), University of Porto, Porto, Portugal

  ⨯
• Ricardo Cruz,

  Affiliation Department of Urology, Portuguese Institute of Oncology, Porto, Portugal

  ⨯
• Teresina Amaro,

  Affiliation Department of Urology, Hospital Pedro Hispano, Matosinhos, Portugal

  ⨯
• Paula A. Oliveira,

  Affiliation Department of Veterinary Sciences, CITAB, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal

  ⨯
• José Alexandre Ferreira ,

  * E-mail: josealexandreferreira@ua.pt (JAF); llarasantos@gmail.com (LLS)

  Affiliations Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal, Mass Spectrometry Center of the University of Aveiro, Campus de Santiago, Aveiro, Portugal

  ⨯
• Lúcio L. Santos

  * E-mail: josealexandreferreira@ua.pt (JAF); llarasantos@gmail.com (LLS)

  Affiliations Experimental Pathology and Therapeutics Group, Portuguese Institute of Oncology, Rua Dr. António Bernardino de Almeida, Porto, Portugal, Health Sciences Faculty of University Fernando Pessoa, Porto, Portugal, Department of Surgical Oncology, Portuguese Institute of Oncology, Porto, Portugal

  ⨯